Investigators conducted a secondary analysis that assessed virologic outcomes following 48 weeks of first-line treatment with dolutegravir/lamivudine in patients with newly diagnosed HIV infection.
Epstein-Barr virus infection may present with liver injury characterized by acute cholestatic hepatitis, as demonstrated in this case.
Researchers conducted a modeling study to determine the projected long-term impact of the COVID-19 pandemic on outcomes associated with hepatitis C virus care.
Forty years after the emergence of HDV, the first anti-HDV therapeutic has been approved by the EMA, indicating the dawn of a new era for this difficult to treat disease
Investigators conducted a study that compared the efficacy of high- vs standard-dose hepatitis B virus revaccination regimens in patients with HIV infection.
Investigators assessed the safety profile and antiviral activity of the agent RO7049389 for the treatment of chronic hepatitis B virus infection.
In this phase 4 non-inferiority trial, researchers compared the effects of short course vs standard course therapy with sofosbuvir-velpatasvir for the treatment of patients with hepatitis C virus.
Researchers conducted a cross-sectional study to assess the impact of subscription-based payment models on the rate of prescription fills for hepatitis C virus medications among individuals in Louisiana and Washington enrolled in Medicaid.
Investigators reported on the hepatitis C virus cascade of care throughout the first few years of a treatment-as-prevention program initiated in Iceland.
The new vial sizes are currently in stock and commercially available in the US.
